At the 2026 JP Morgan Healthcare Conference in San Francisco, Medtronic’s CFO Shantanu Agrawal and CEO Geoff Martha emphasized that the company holds more than $15 billion in available liquidity and an undrawn credit facility of $10 billion to fund strategic acquisitions. They noted that Medtronic’s strong free cash flow—approximately $6 billion annually—coupled with disciplined leverage targets (net debt to EBITDA below 3.0x), positions the company to pursue multiple bolt-on and transformational deals without compromising its investment-grade credit rating. Management signaled priority areas including robotics, minimally invasive therapies and digital health, where recent internal R&D spend of $2.1 billion has generated a robust pipeline of next-generation products. Investors will watch for guidance on potential deal sizes and timing, with management indicating a preference for targets that can contribute at least $200 million in incremental EBIT within two years post-close.

Medtronic announced a collaboration with Precision Neuroscience to integrate the Layer 7 brain–computer interface into its StealthStation surgical navigation system. The co-developed solution will combine high-resolution cortical mapping with real-time 3D structural imaging in the operating room. Precision’s minimally invasive electrode arrays have demonstrated the ability to record 1,024 channels of cortical activity at 30 kHz per channel in pilot clinical studies, while StealthStation’s navigation accuracy of under 1 mm supports precise instrument guidance. Management forecasts that the integrated platform could address an addressable market of $850 million by 2030, reflecting the 40,000 annual functional neurosurgeries in North America and Europe. The deal terms include an upfront payment of $50 million and potential milestone payments totalling $200 million tied to clinical validation and regulatory approvals.

Medtronic Diabetes secured U.S. FDA 510(k) clearance for its MiniMed Go™ Smart Multiple Daily Injection system, integrating the InPen smart insulin pen with Abbott’s Instinct CGM sensor in a single mobile app. Clinical data from a cohort of 1,852 Type 1 users showed Time in Range improvement from 55.7% to 67.2% when users responded to over 75% of missed-dose alerts within one hour. The system is cleared for patients aged 7 and up, with pediatric use (ages 2–6) under caregiver supervision. Management projects that the new MDI solution could reach 500,000 users in its first two years, driving incremental diabetes segment revenue growth of 8–10% annually. A commercial launch is slated for spring 2026, with initial marketing focused on U.S. endocrinology networks and direct-to-consumer digital channels.